Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-927 + budigalimab + modified FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ABBV-927 + budigalimab + modified FOLFIRINOX is a combination investigational regimen for cancer, studied primarily in advanced or metastatic solid tumors. **ABBV-927** is an experimental anti-CD40 agonist monoclonal antibody immunotherapy developed to stimulate immune responses against cancer cells. **Budigalimab** (also known as ABBV-181) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune activity. **Modified FOLFIRINOX** is a cytotoxic chemotherapy regimen containing oxaliplatin, irinotecan, leucovorin (folinic acid), and 5-fluorouracil, often with modifications in dosing for tolerability. This combination targets the tumor with both immune activation and direct cytotoxic mechanisms and is being evaluated in phase 1 trials for the treatment of locally advanced or metastatic solid tumors, including pancreatic and other cancers[1][5][7].
- Other names
- ABBV-181 + ABBV-927 + modified FOLFIRINOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)MesothelinTOP1 (DNA Topoisomerase I)CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on ABBV-927 + budigalimab + modified FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-927 + budigalimab + modified FOLFIRINOX.